Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexion Not Scared Of Amgen Biosimilar Threat To Soliris

Companies Settled Eculizumab Litigation In US Earlier This Year

Executive Summary

Alexion Pharmaceuticals is confident of its strategy to switch patients from Soliris to Ultomiris as the threat of biosimilar competition to the former looms. But launching a biosimilar to Soliris alone will be a challenge, the company maintains.

You may also be interested in...



Amgen’s Mvasi Biosimilar Overtakes Avastin In The US

Amgen enters 2021 with a five-strong global biosimilars portfolio, spearheaded by its market-leading bevacizumab and trastuzumab products in the US. Management explained the contrasting fates of the two oncology biosimilars as it published full-year financial results.

Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025

Amgen will be able to launch its US Soliris biosimilar around two years ahead of patent expiry under a settlement agreement. The brand’s manufacturer, Alexion, discussed the threat as AstraZeneca pounced with a $39bn takeover agreement.

Amgen Chooses To Settle In US Soliris IPR Tussle

Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel